Information Provided By: 
Fly News Breaks for February 28, 2018
AMED
Feb 28, 2018 | 05:05 EDT
Jefferies analyst Brian Tanquilut raised his price target for Amedisys to $70 and reiterates a Buy rating on the shares following the company's Q4 results. Elevated expenses masked improving sales trends, Tanquilut tells investors in a post-earnings research note. He believes the regulatory and demand outlooks for home health appears "favorable" and that competitors are occupied with deal integrations.
News For AMED From the Last 2 Days
There are no results for your query AMED
